neurotrophic receptor tyrosine kinase | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

15,697 results for “neurotrophic receptor tyrosine kinase”

Trials

View all 7605 →

A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib

26 participants · First posted Mar 24, 2021

Not yet recruiting

Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion

10 participants · First posted May 20, 2026

Serum TAM Receptor Tyrosine Kinase Ligands in Acute Pancreatitis

896 participants · First posted Jun 15, 2025

Drugs

View all 1815 →

Larotrectinib(Vitrakvi)

Conditions: NTRK1 Fusion Positive, NTRK2 Fusion Positive +1 more

C₂₁H₂₂F₂N₆O₂ · Rx

BNN27

Organizations

View all 46 →

Regeneron Pharmaceuticals

United States

Arvinas Estrogen Receptor, Inc.

United States

Arvinas Androgen Receptor, Inc.

United States

News

View all 6231 →

Next-Generation TRK Inhibitors Show Promise in Treating NTRK Fusion-Positive Cancers

Larotrectinib Shows High Efficacy in Pediatric Solid Tumors with NTRK Fusion

FDA Phases Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

Page 1 of 1570